首页> 外文期刊>Computational intelligence and neuroscience >An Efficient Combination among sMRI, CSF, Cognitive Score, and APOE ε4 Biomarkers for Classification of AD and MCI Using Extreme Learning Machine
【24h】

An Efficient Combination among sMRI, CSF, Cognitive Score, and APOE ε4 Biomarkers for Classification of AD and MCI Using Extreme Learning Machine

机译:SMRI,CSF,认知评分和ApoEε4生物标志物中的高效组合,用于使用极限学习机进行广告和MCI的分类

获取原文
           

摘要

Alzheimer’s disease (AD) is the most common cause of dementia and a progressive neurodegenerative condition, characterized by a decline in cognitive function. Symptoms usually appear gradually and worsen over time, becoming severe enough to interfere with individual daily tasks. Thus, the accurate diagnosis of both AD and the prodromal stage (i.e., mild cognitive impairment (MCI)) is crucial for timely treatment. As AD is inherently dynamic, the relationship between AD indicators is unclear and varies over time. To address this issue, we first aimed at investigating differences in atrophic patterns between individuals with AD and MCI and healthy controls (HCs). Then we utilized multiple biomarkers, along with filter- and wrapper-based feature selection and an extreme learning machine- (ELM-) based approach, with 10-fold cross-validation for classification. Increasing efforts are focusing on the use of multiple biomarkers, which can be useful for the diagnosis of AD and MCI. However, optimum combinations have yet to be identified and most multimodal analyses use only volumetric measures obtained from magnetic resonance imaging (MRI). Anatomical structural MRI (sMRI) measures have also so far mostly been used separately. The full possibilities of using anatomical MRI for AD detection have thus yet to be explored. In this study, three measures (cortical thickness, surface area, and gray matter volume), obtained from sMRI through preprocessing for brain atrophy measurements; cerebrospinal fluid (CSF), for quantification of specific proteins; cognitive score, as a measure of cognitive performance; and APOE ε4 allele status were utilized. Our results show that a combination of specific biomarkers performs well, with accuracies of 97.31% for classifying AD vs. HC, 91.72% for MCI vs. HC, 87.91% for MCI vs. AD, and 83.38% for MCIs vs. MCIc, respectively, when evaluated using the proposed algorithm. Meanwhile, the areas under the curve (AUC) from the receiver operating characteristic (ROC) curves combining multiple biomarkers provided better classification performance. The proposed features combination and selection algorithm effectively classified AD and MCI, and MCIs vs. MCIc, the most challenging classification task, and therefore could increase the accuracy of AD classification in clinical practice. Furthermore, we compared the performance of the proposed method with SVM classifiers, using a cross-validation method with Alzheimer’s Disease Neuroimaging Initiative (ADNI) datasets.
机译:阿尔茨海默病(Ad)是痴呆症最常见的原因和渐进性神经变性病症,其特征在于认知功能下降。症状通常会逐渐出现并随着时间的推移恶化,严重足以干扰个别日常任务。因此,AD和前驱阶段的准确诊断(即,轻度认知障碍(MCI))对于及时治疗至关重要。随着广告本身是动态的,广告指标之间的关系尚不清楚,随着时间的推移而变化。为了解决这个问题,我们首先旨在调查具有广告和MCI和健康控制(HCS)的个体之间萎缩模式的差异。然后我们使用多个生物标志物,以及基于过滤器和包装器的特征选择和基于极端的学习机器(ELM-)的方法,具有10倍的分类交叉验证。越来越多的努力侧重于使用多种生物标志物,这对于诊断广告和MCI来说是有用的。然而,尚不识别最佳组合,并且大多数多模式分析仅使用从磁共振成像(MRI)获得的体积措施。到目前为止,解剖结构MRI(SMRI)措施也主要是单独使用。因此,尚未探索使用解剖学MRI进行AD检测的全部可能性。在本研究中,通过预处理为脑萎缩测量,从SMRI获得三种措施(皮质厚度,表面积和灰质体积);脑脊髓液(CSF),用于定量特定蛋白质;认知得分,作为认知性能的衡量标准;使用Apoeε4等位基因状态。我们的研究结果表明,特定生物标志物的组合表现良好,分类为3.3.72%的COMI,91.72%,MCI与MCI的87.91%,MCI与MCIC的87.91%,分别为97.31%,分别为87.38% ,使用所提出的算法进行评估。同时,来自接收器的曲线(AUC)下的区域与多个生物标志物组合的接收器操作特征(ROC)曲线提供了更好的分类性能。所提出的特征组合和选择算法有效地分类了广告和MCI,而MCIS与MCIC,最具挑战性的分类任务,因此可以提高临床实践中广告分类的准确性。此外,我们使用具有阿尔茨海默病神经影像倡议(ADNI)数据集的交叉验证方法对SVM分类剂进行了与SVM分类剂的性能进行了比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号